Phase II Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma Patients
Interventional
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Overall response rate
12 months
No
Lev Demidov, MD, D.Sc.
Principal Investigator
N.N. Blokhin Russian Cancer Research Center
Russia: Ministry of Health of the Russian Federation
CRT-06.CAP
NCT01182142
September 2007
August 2010
Name | Location |
---|